MelanomaArchives
Treatment-refractory immune checkpoint inhibitor-induced hemophagocytic lymphohistiocytosis in the setting of adjuvant pembrolizumab for resected stage IIC melanoma: a case report
Melanoma 3 min.
Hemophagocytic lymphohistiocytosis (HLH) is a dysregulated systemic inflammatory state with persistent activation of natural killer (NK) cells, cytotoxic T lymphocytes, and macrophages, leading to elevation of serum proinflammatory cytokines causing immune-related multiorgan damage. HLH can be broadly...
Identification of two distinct uveal melanoma subtypes based on the immune cell infiltration of the primary tumour
Melanoma 4 min.
Uveal melanoma (UM) is the most common intraocular malignancy, accounting for approximately 3% of all melanoma cases [1]. Disease arises from melanocytes in the uvea tract of the eye with the majority of cases affecting the choroid and less frequently the iris and ciliary body. Mean patient age at diagnosis...
Anti-PD-1 treatment response is associated with the influx of circulating myeloid and T-cell subsets into the metastatic melanoma tumor microenvironment
Melanoma 9 min.
Immune checkpoint inhibitors (ICIs) represent a breakthrough treatment of advanced (i.e. irresectable metastatic) melanoma, as the use of anti-PD-1 anti-CTLA-4 combination therapy increases median overall survival (OS) from 6-9 months to nearly six years [1, 2, 3–4]. However, more than half of...
Diagnostic value of 18F-FDG PET/CT in the follow-up of metastatic uveal melanoma
Melanoma 4 min.
Uveal melanoma (UM) is a rare ocular tumor and is considered the most common primary malignant tumor in the adult eye [1]. In the China, the annual incidence rate is about 0.5 per million, accounting for 5% of all melanoma. In 90% of cases, it originates from the choroid, 7% from the ciliary body, and...
